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Cardiac thyroid-hormone signaling is a critical determinant of cellular metabolism and 
function in health and disease. A local hypothyroid condition within the failing heart in 
rodents has been associated with the re-expression of the fetally expressed thyroid-hor-
mone-inactivating enzyme deiodinase type III (Dio3). While this enzyme emerges as a 
common denominator in the development of heart failure, the mechanism underlying its 
regulation remains largely unclear. In the present study, we investigated the involvement 
of microRNAs (miRNAs) in the regulation of Dio3 mRNA expression in the remodeling 
left ventricle (LV) of the mouse heart following myocardial infarction (MI). In silico analysis 
indicated that of the miRNAs that are differentially expressed in the post-MI heart, miR-
214 has the highest potential to target Dio3 mRNA. In accordance, a luciferase reporter 
assay, including the full-length 3′UTR of mouse Dio3 mRNA, showed a 30% suppres-
sion of luciferase activity by miR-214. In the post-MI mouse heart, miR-214 and Dio3 
protein were shown to be co-expressed in cardiomyocytes, while time-course analysis 
revealed that Dio3 mRNA expression precedes miR-214 expression in the post-MI LV. 
This suggests that a Dio3-induced decrease of T3 levels is involved in the induction of 
miR-214, which was supported by the finding that cardiac miR-214 expression is down 
regulated by T3 in mice. In vitro analysis of human DIO3 mRNA furthermore showed 
that miR-214 is able to suppress both mRNA and protein expression. Dio3 mRNA is a 
target of miR-214 and the Dio3-dependent stimulation of miR-214 expression in post-MI 
cardiomyocytes supports the involvement of a negative feedback mechanism regulating 
Dio3 expression.
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inTrODUcTiOn
Myocardial infarction (MI) is one of the major causes of heart 
failure in Western society (1). The sudden interruption of blood 
flow results in cardiomyocyte death by necrosis and subsequent 
fibrosis of the affected part of the left ventricle (LV). The associ-
ated increase in cardiac load of the non-infarcted region of the 
heart triggers functional and structural remodeling of the spared 
myocardium aimed at maintaining cardiac output (2, 3). The 
process of remodeling includes hypertrophy of cardiomyocytes, 
i.e., primarily lengthening by addition of sarcomeres in series, 
and marked changes in gene expression, including re-expression 
of part of the fetal gene program. Progressive remodeling, LV 
dilation, and the associated increase in wall stress often culminate 
in chronic heart failure. The underlying changes in gene expres-
sion are mediated by a multitude of signal transduction pathways 
involving transcriptional regulation, as well as non-coding tran-
scripts, such as microRNAs (miRNAs), that affect mRNA stability 
or translation efficiency (3–6).
One of the genes that is re-expressed as part of the fetal gene 
program in various models of cardiac hypertrophy and heart 
failure is the thyroid-hormone-inactivating enzyme, deiodinase 
type III (Dio3) (7–11). Dio3 belongs to a family of 25 so called 
selenoproteins that require a mRNA stem loop structure located 
in the 3′UTR region, termed a selenocysteine insertion sequence 
(SECIS) element, for incorporation of a selenocysteine critical for 
enzymatic activity [reviewed by Berry et al. (12)]. Dio3 converts 
the active form of thyroid hormone, triiodothyronine (T3), to 
the inactive metabolite diiodothyronine (3,3′-T2) [reviewed by 
Gereben et al. (13)]. In both mouse and rat models of ventricular 
failure, the re-expression of Dio3 in the remodeling LV is associ-
ated with a ~50% reduction of tissue T3 levels and a similarly 
reduced T3 transcriptional activity in cardiomyocytes in vivo (8, 
9). This local impairment of T3 signaling is suggested to play a role 
in the development of cardiac dysfunction given the fact that T3 
is an important regulator of cardiac contractility and metabolism 
[reviewed by Klein and Ojamaa (14)].
Expression of Dio3 has been shown to be regulated by 
transforming growth factor β (Tgfβ), mitogen-activated protein 
kinases (Mapk), sonic hedgehog (Shh), and hypoxia-inducible 
factor-1α (Hif-1α) (9, 15, 16). Although the signaling cascades 
involving these factors are all implicated in cardiac remodeling 
[reviewed by Pol et  al. (17)], none of these have as yet been 
shown to be involved in the re-expression of Dio3 in the heart. 
Given the strict spatiotemporal regulation of Dio3 activity dur-
ing fetal development, such as in the retina and cochlea (18, 19), 
Dio3 expression is considered a likely candidate for regulation 
by miRNAs.
MicroRNAs are evolutionary conserved small non-coding 
RNA molecules of approximately 22 nucleotides long that are 
encoded within the genomes of almost all eukaryotes. In gen-
eral, miRNAs post-transcriptionally regulate protein synthesis 
through base pairing with sufficiently complementary sequences 
in the 3′-untranslated region (3′UTR) of target mRNAs (20). 
Recent studies have shown an important role for miRNAs in the 
regulation of cardiac gene expression by virtue of their ability 
to induce degradation of specific target mRNAs or reduce the 
efficiency of translation (5, 21). Although up or down regulation 
of miRNAs is generally considered to fine-tune gene expression, 
several studies have provided insight into the critical roles of 
individual miRNAs in the different processes associated with 
development and disease, and in particular the progression of 
heart failure (21–24).
In this study, we therefore investigated whether miRNAs play 
a role in the regulation of Dio3 expression in the remodeling 
heart, using the post-MI model in the mouse. In a previous study 
using this model, we identified miRNAs that were differentially 
modulated (25). In silico analysis performed in the present study 
identified only one of these miRNAs as potentially targeting Dio3. 
However, this miR-214-3p (hereafter referred to as miR-214) was 
upregulated in MI, implying suppression of Dio3 expression. 
Upregulated expression of the highly conserved miR-214 in 
cardiac hypertrophy and heart failure has been demonstrated 
in several cardiac miRNA profiling studies in both human and 
experimental animal models (21, 24–26). It has been shown that 
elevated expression levels of miR-214 induce hypertrophy (21, 
27) by suppressing peroxisome proliferator-activated receptor δ 
(Pparδ) (27). In contrast to the apparently unfavorable effects of 
miR-214 in cardiac hypertrophy and heart failure, miR-214 has 
been shown to protect the heart from ischemic injury in a knock-
out model, by suppressing the expression of the sodium calcium 
exchanger Ncx1 and consequently preventing Ca2+ overload of 
cardiomyocytes and subsequent cell death (22).
Given the observed role of miR-214 in cardiac remodeling, we 
tested its possible relevance for the regulation of Dio3 expression. 
Our results show that Dio3 is a target of miR-214 and suggest that 
a negative feedback mechanism exists, in which the upregulation 
of miR-214 dampens the MI-induced upregulation of Dio3, limit-
ing the reduction of cardiac T3 signaling.
MaTerials anD MeThODs
Prediction of mirnas Targeting Dio3
Putative miRNAs targeting Dio3 were identified by combining the 
results of different prediction databases: Targetscan v5.2, PicTar 
v03-2007, mirDB, and MicroCosm v5. Only miRNAs that were 
called by all four databases were considered for further analysis.
luciferase reporter experiments
Approximately 7.5 × 104 HEK293 cells were seeded per well in 
48-well plates in growth medium (DMEM containing 10% FBS, 
1% NEAA, 1% sodium pyruvate, and 1% P/S). The next day, at 
50% confluence, medium was changed to 200  μl DMEM per 
well. To increase the accuracy of the determination of miR-214- 
dependent luciferase activity, cells were transfected with 50 ng 
of a single dual-luciferase reporter plasmid containing the Dio3 
3′-UTR downstream of the Renilla luciferase gene (RLuc). Firefly 
luciferase activity (FLuc) was used to correct for differences 
in transfection efficiency. To mimic or inhibit miRNA action, 
chemically modified double-stranded RNA molecules were 
added. These included Pre-miR-214 (100 nM); a combination of 
Pre-miR-214 (50 nM) and Anti-miR-214 (50 nM); or negative 
control miR#1 (100 nM) (Ambion, Foster City, CA, USA). Both 
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plasmids and miRNAs were transfected using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA, USA). After 6 h, the transfec-
tion medium was replaced by growth medium. Forty-eight hours 
after the start of transfection, medium was removed and cells 
were lysed for 15 min in 50 μl lysis buffer (Promega, Madison, 
WI, USA) and the activity of RLuc and FLuc luciferase activity 
was assessed using the Dual-Luciferase®Reporter Assay System 
(Promega, Madison, WI, USA), according to manufacturer’s 
instructions.
Mouse Model of Myocardial infarction
A total of 12 C57Bl/6J mice (Harlan, 10–12 weeks old) of either 
sex were randomly assigned to the sham-operated group or MI 
group, weighed and anesthetized. MI was induced by ligation of 
the left coronary artery (LAD) and echocardiography measure-
ments were performed as previously described (28, 29). Briefly, 
under anesthesia (2.5% isoflurane in a mixture of air and O2), a 
thoracotomy was performed at the fourth left intercostal space 
and the LAD was permanently ligated. The occlusion was con-
firmed by the slight change in color of the anterior wall of the 
LV downstream of the ligature. Sham-operated mice underwent 
the same procedure except for the occlusion of the LAD. After 
1  week, echocardiography was used to establish the reduced 
contraction of the LV free wall. LV tissue from sham animals 
and non-infarcted, i.e., spared LV tissue from MI animals was 
collected, frozen in liquid nitrogen and stored at −80°C. In 
addition, we used LV tissue (post-MI days 3, 5, 7, 14, 35, or 56) 
from previous experiments (8) that were performed according to 
above-described protocol.
Mouse Model of hyperthyroidism
Left-ventricular samples from a previous study were used to 
assess miR-214 expression (30). Briefly, in this study two groups 
of six male C57BL/6 mice (age 10–12  weeks, Charles River) 
were used. Both groups were allowed ad libitum access to food 
containing propylthiouracil (PTU) (Teklad +  0.15% PTU) for 
41  days to induce hypothyroidism. Animals were maintained 
on this diet and six mice were injected intraperitoneally with a 
supra-physiological dose of 5 μg T3 in 20 μl saline (correspond-
ing to 0.21–0.24 μg T3/g BW) at days 42, 43, and 44, while the 
remaining six mice were injected with 20 μl saline. Animals were 
sacrificed at day 45. Left-ventricular tissue from hypothyroid and 
hyperthyroid mice was collected, frozen in liquid nitrogen and 
stored at −80°C until analysis.
All experiments performed on animals complied with the 
Guide for Care and Use of Laboratory Animals of the National 
Institutes of Health (NIH Publication no. 86–23, revised 1996) 
and were approved by the Institutional Animal Care and Use 
Committees of VU University Medical Center Amsterdam.
Quantitative Pcr and mirna analysis
Total RNA was isolated from LV tissue of sham, post-MI, hypo-, 
and hyperthyroid mice using mirVana PARIS kit for miRNA 
(Ambion, Foster City, CA, USA) or TriPure for mRNA (Roche, 
Basel, Switzerland) and treated with DNaseI (Qiagen, Venlo, The 
Netherlands) to remove remnants of genomic DNA, followed 
by reverse transcription reaction with either Cloned AMV 
First Strand synthesis kit (Invitrogen, Carlsbad, CA, USA) or 
with miRCURY LNA Universal cDNA synthesis kit II (Exiqon, 
Vedbæk, Denmark). Expression levels of atrial natriuretic fac-
tor (Anf), MHCα (Myh6), MHCβ (Myh7), and Dio3 mRNA 
were determined by qPCR using specific primers (Table S1 in 
Supplementary Material) and standard cycle parameters on an 
Applied Biosystems model 7500 (Applied Biosystems, Foster 
City, CA, USA) with hypoxanthine-guanine-phosphoribosyl-
transferase (Hprt) as correction factor. Expression levels of 
miR-214-3p were analyzed using miRCURY LNA miRNA 
primers and normalized against U6 snRNA (Exiqon, Vedbæk, 
Denmark).
In Situ hybridization
Before tissue sectioning, all equipment was heat-treated or cleaned 
with RNAzap (Sigma-Aldrich, St. Louis, MO, USA) to eliminate 
RNase contamination. Paraformaldehyde-fixed and paraffin-
embedded sections (6 μm) were deparaffinized according to the 
manufacturer’s instructions for in  situ hybridization (Exiqon, 
Vedbæk, Denmark) (31). Sections were incubated with 5 μg/ml 
proteinase-K for 30 min at 37°C, washed in PBS and immediately 
dehydrated using solutions with increasing concentration of 
ethanol. When dry, slides were placed in a specially designed 
hybridization chamber. To prepare the double-digoxigenin (DIG) 
miRCURY LNA microRNA Detection probe (Exiqon, Vedbæk, 
Denmark), an aliquot was heated to 90°C for 4 min and diluted to 
40 nM in ISH buffer (Exiqon, Vedbæk, Denmark). Approximately 
50 μl was applied directly on the dried tissue section. The sealed 
hybridization chamber was placed in an oven at an optimized 
temperature of 57°C for 1 h. Slides were then placed in a glass jar 
containing 5 × SSC at room temperature. Stringent washes were 
performed in pre-heated SSC buffers (hybridization temperature, 
57°C) of 5  min each: once in 5 ×  SSC, twice in 1 ×  SSC, and 
twice in 0.2 × SSC. Next, the slides were placed in 0.2 × SSC at 
room temperature and transferred to a glass jar containing PBS 
containing 0.1% Tween-20. To prevent non-specific binding 
of anti-DIG, sections were blocked using PBS containing 0.1% 
Tween-20 and 2% goat serum for 15 min at room temperature. 
Alkaline-phosphatase (AP) conjugated anti-DIG (Roche, Basel, 
Switzerland) was diluted 1:500 in blocking buffer and incubated 
for 2 h at room temperature. Slides were washed three times with 
PBS containing 0.1% Tween-20. Alkaline-phosphatase substrate 
[3.4 μl NBT, 3.5 μl BCIP, 2.4 μl 1.25 mM Levamisole, 5 μl 10% 
Tween-20 in 1  ml substrate solution: 0.1M Tris pH 9.5, 0.1M 
NaCl, 50  mM MgCl2 (32)] was applied at room temperature 
and replaced with fresh solution after 1 h and incubated over-
night. Placing the slides two times in PBS for 5 min stopped the 
enzymatic reaction. For counterstaining the sections, we applied 
100 μl Nuclear Fast Red (Vector Labs, Burlingame, CA, USA) 
on each section for 1 min and subsequently rinsed the slides for 
10 min with running tap water. Before mounting the slides with 
Entellan™ (Merck Darmstadt, Germany), slides were dehydrated 
using an increasing gradient of ethanol solutions and twice in 
xylene for 5 min.
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histochemistry
Dio3 immunohistochemistry was performed as previously 
described (8). Briefly, paraformaldehyde-fixed and paraffin-
embedded LV tissue sections (4  μm) were deparaffinized and 
rehydrated and exposed for 20  min to 0.02  M HCl. Epitope 
retrieval was performed by placing the sections at 93°C for 
10 min in 10 M citrate buffer (pH 6.0). Sections were incubated 
with antibody 718 at 1:50 dilution at 37°C for 1 h and processed 
with Envision+ reagents (Dako, Glostrup, Denmark).
Polyclonal antibody 718 was raised in rabbit against the 
synthetic peptide KPEPEVELNSEGEEVP of the N-terminus 
of human DIO3 (amino acid residues 53–68). This antibody 
was kindly provided by Prof. D. Salvatore (University of Naples 
Federico II, Department of Molecular and Clinical Endocrinology 
and Oncology, Naples, Italy).
cell culture and Western Blotting
Approximately 1.0 ×  105 COS-7 cells were seeded per well in 
12-well plates in DMEM containing 10% FBS, 1% P/S. The next 
day, at 50–60% confluence, medium was refreshed. Cells were 
co-transfected with 100–400 ng full-length human DIO3 (wtD3) 
pcDNA3 vector (33). As a control, a mutant DIO3 expression vec-
tor was used that results in the replacement of the selenocysteine 
residue in the active center of the enzyme with cysteine (CysD3). 
Mimic-214-3p or negative miRNA control #1 was co-transfected 
at a final concentration of 500  nM (Ambion, Foster City, CA, 
USA). To isolate RNA and protein, medium was removed after 
24 h, and cells were washed with PBS before being lysed with 50 μl 
lysis buffer (mirVana PARIS kit, Ambion, Foster City, CA, USA).
COS-7 cell lysates were separated on 15% SDS-PAGE gels and 
transferred to PVDF membrane by a semi-dry blotting system 
(Bio-Rad, Hercules, CA, USA). The membranes were cut into 
two at the 25  kDa weight marker and blocked with 5% (w/v) 
BSA in TBS containing 0.1% Tween (TBS-T) overnight at 4°C. 
Subsequently, the part of the membrane containing proteins 
larger than 25  kDa was incubated with antibody 677 (1:300), 
and the part of the membrane containing proteins smaller than 
25 kDa was incubated with antibody 675 (1:1000) in 5% BSA in 
TBS-T for 2  h at room temperature. Membranes were washed 
three times for 10 min with TBS-T, followed by incubation with 
horseradish-peroxidase labeled goat anti-rabbit IgG in TBS-T 
(1:1000) for 1 h at room temperature and three times for 10 min 
with TBS-T. Bands were visualized using chemiluminescence 
(Amersham, Little Chalfont, UK) and scanned by LAS-3000 
(Fujifilm Life Science, Stamford, CT, USA). Band intensity was 
quantified using Aida 4.21 (Raytest, Straubenhardt, Germany) 
and gel loading normalized to α-actinin (Sigma-Aldrich, St. 
Louis, MO, USA).
Polyclonal antibody 677 was raised in rabbit against the 
synthetic peptide RYDEQLHGARPRRV of the C-terminus of 
human DIO3 (amino acid residues 265–278) (33). Polyclonal 
antibody 675 was raised in rabbit against the synthetic peptide 
RRGKPEPEVELNS of the N-terminus of human DIO3 (amino 
acid residues 50–62). Both constructs and primary antibod-
ies were kindly provided by Prof. T. Visser (Erasmus Medical 
Center, Rotterdam, The Netherlands). To correct for variations 
in transfection efficiency, DIO3 mRNA and protein levels were 
normalized to the mRNA level of the neomycin-resistance gene, 
expressed from the DIO3 pcDNA3 vectors.
Dio3 activity
Dio3 activity in LV homogenates was determined as described 
previously (33) with minor modifications. Reaction mixtures 
contained approximately 200,000 cpm of outer-ring-labeled T3 
(3′-125I T3) and 0.25 mg protein in a final volume of 0.05 ml 0.1 M 
phosphate buffer (pH 7.2) containing 2 mM EDTA and 10 mM 
DTT. Mixtures were incubated for 60 min at 37°C and the reac-
tion was stopped by addition of 0.05 ml ice-cold ethanol. After 
centrifugation, 0.075 ml of the supernatant was mixed with an 
equal volume of 0.02 M ammonium acetate (pH 4.0), and 0.1 ml 
of the mixture was applied to a 250 mm ×  4.6 mm Symmetry 
C18 column connected to an Alliance HPLC system (Waters 
Chromatography Division, Millipore Corp., Milford, MA, USA) 
and eluted with a 15-min linear gradient of acetonitrile (28–42%) 
in 0.02  M ammonium acetate (pH 4) at a flow rate of 1.2  ml/
min. Radioactivity in the eluate was monitored online using a 
Radiomatic A-500 flow scintillation detector (Packard, Meriden, 
CT, USA) and product formation by the inner-ring deiodination 
activity, i.e., (3′-125I T2) was quantified.
statistics
Data analysis was performed using Graphpad Prism version 6 
(Graphpad, San Diego, CA, USA). Statistical significance was 
tested using a two-tailed Student t-test and accepted at p < 0.05.
resUlTs
In Silico analyses: Dio3 is a Bona Fide 
Target of mir-214
To identify potential miRNAs involved in regulating Dio3 
expression in the remodeling LV, we performed in silico analysis 
using four different prediction databases. MiR-214 was identified 
as having a high potential to target the 3′UTR of Dio3. A site 
complementary to the seed region of miR-214, which is highly 
conserved among species, was found to be located in the SECIS 
element, which is a secondary RNA structure (Figure 1).
mir-214 expression is increased in the 
remodeling lV of the Post-Mi heart
In a previous study, we identified miR-214 as a differentially 
regulated miRNA in the remodeling LV of the post-MI mouse 
heart compared to the LV of sham-operated mice, using TaqMan 
Megaplex array analysis of all 641 mouse miRNAs known at the 
time. Here, we validated the increased expression level of miR-
214 in the post-MI heart using quantitative RT PCR analysis with 
U6 snRNA as correction factor, showing a significant threefold 
increase in miR-214 expression in the LV tissue 7 days post-MI 
surgery compared to sham-operated mice (Figure 2). Previous 
studies conducted by our group already established an approxi-
mately sixfold increased expression of Dio3 mRNA using the 
same model (8, 25).
FigUre 2 | increased mir-214 expression in the post-Mi lV. Mir-214 
expression levels were determined by quantitative RT PCR analysis in remote 
LV tissue from sham and MI animals isolated at day 7 post surgery. U6 
snRNA expression levels were used as correction factor. Values are 
means ± SEM, n = 6, normalized to the sham level, *p < 0.05.
FigUre 1 | conserved mir-214 target site in the 3′-UTr of Dio3. In silico analysis predicts a target sequence for miR-214 in the stem of SECIS element of the 
3′UTR of Dio3 in mice, which is highly conserved among species. (Source: Targetscan and microRNA.org).
FigUre 3 | Dio3 is targeted by mir-214. A dual-luciferase construct 
containing the complete Dio3 3′UTR downstream of the Renilla luciferase gene 
was used to analyze the interaction between miR-214 and the 3′UTR of Dio3. 
Renilla luciferase activity (RLuc) is expressed relative to firefly luciferase activity 
(FLuc), correcting for differences in transfection efficiency. Four independent 
transfections were performed in duplicate. No-miR: control without co-
transfection; ctrl-miR: + negative control/scrambled miR-1; P214: + Pre-
miR-214; PA214: + Pre-miR-214 and Anti-miR-214. Values are means ± SEM, 
n = 4, normalized to the RLuc/Fluc ratio in the no-miR group, *p < 0.05.
March 2016 | Volume 7 | Article 225
Janssen et al. MicroRNA-214 and Cardiac Dio3 Regulation
Frontiers in Endocrinology | www.frontiersin.org
Validation of Dio3 as a Target of mir-214
To investigate whether miR-214 targets Dio3, we performed 
in vitro luciferase reporter experiments. A DNA-construct that 
contained the mouse Dio3 3′UTR inserted downstream of a 
luciferase reporter gene was transiently transfected into HEK293 
cells. The results show a 30% reduction in RLuc activity when 
co-transfecting the reporter construct for 24 h with Pre-miR-214, 
relative to the “no-miR.” Compared to the condition with a control 
miRNA, this reduction was 22%. The addition of Anti-miR-214 
to the transfection mix containing miR-214 abolished the repres-
sion (Figure  3). These luciferase reporter experiments support 
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the in silico prediction that binding of miR-214 to the Dio3 3′UTR 
results in repression of Dio3 protein expression.
analysis of the role of mir-214 in the 
Translation of DiO3 in Transfected cOs 
cells and the involvement of the secis 
element
Analysis of the 3′UTR of Dio3 showed the presence of a highly 
conserved miR-214 target site in the SECIS element (Figure 1), 
which is present in both mouse and human DIO3. Since the 
SECIS element is essential for the incorporation of selenocyst-
eine in DIO3, it led us to the question whether miR-214 might 
also interfere with DIO3 translation at this level. The kind gift 
by prof. T. Visser of a DNA-construct containing the full-length 
human DIO3 enabled us to investigate this possible interference 
in transfection experiments using cultured COS-7 cells.
Several studies showed that manipulation of the SECIS element 
results in increased levels of truncated DIO3. Therefore, COS-7 
cells transfected with the plasmid containing the full-length 
human DIO3 (wtD3) together with mimic-214 or negative con-
trol miR-1 were analyzed for full-length (36 kDa) and truncated 
(18 kDa) DIO3 protein levels using western blotting. Expression 
levels were corrected using neomycin mRNA, transcribed from 
the same plasmid, as a control for transfection efficiency.
The specificity of Ab 677 and Ab 675 for the full-length and the 
truncated DIO3, respectively, was validated by transfecting COS-7 
cells with increasing amounts of wtD3 plasmid DNA (Figure 4A). 
COS-7 cells transfected with expression vector encoding CysD3 
(which exclusively yields full-length protein) confirmed the anti-
body specificity of Ab 675 against truncated DIO3 (Figure 4B). 
Co-transfecting the wtD3 plasmid with mimic miR-214 caused 
a ~13% reduction in mRNA expression when compared to cells 
co-transfected with negative control miR-1 (Figure 4C). Western 
blot analysis showed besides significantly reduced full-length 
DIO3 protein levels (~40%) (Figure  4C), reduced truncated 
DIO3 protein levels (~50%) (Figure  4C). However, the ratio 
of 36 over 18 kDa proteins remained unchanged (Figure S2 in 
Supplementary Material). This suggests that binding of miR-214 
to the DIO3 3′UTR does not interfere with selenocysteine incor-
poration. The results indicate that binding of miR-214 results in 
a decreased DIO3 mRNA stability, and although the reduction of 
DIO3 protein levels is larger than that of DIO3 mRNA, it cannot 
be inferred from these data that DIO3 translation efficiency is also 
affected by miR-214.
Dio3 and mir-214 are co-expressed in 
adult cardiomyocytes
In a previous study, a heterogeneous, cardiomyocyte-specific 
expression pattern of Dio3 was observed in the post-MI LV (8). 
Based on the finding that miR-214 targets Dio3, we expected 
cardiomyocytes expressing a high level of Dio3 protein to have 
a low expression level of miR-214, and vice  versa. Therefore, 
we performed miR-214 in  situ hybridization and Dio3 immu-
nohistochemistry on serial sections of post-MI LV tissue. 
A heterogeneous Dio3 expression pattern was again observed 
(Figure 5). Surprisingly, miR-214 in situ hybridization revealed 
a similar heterogeneous pattern, with the majority of miR-214 
positive cardiomyocytes co-expressing Dio3 (Figure  5). This 
suggests either that Dio3 and 214-miRNA are coordinately, but 
independently upregulated, or that the expression of both is 
mechanistically linked.
Dio3 expression Precedes mir-214 
expression in the Post-Mi lV
Previous work conducted by our group revealed a time-dependent 
increase in both Dio3 expression and activity in the post-MI heart 
compared to sham animals (8). To further explore the possible 
interaction between Dio3 and miR-214 expression, we analyzed 
miR-214 expression at 3, 5, 7, 14, 28, and 56 days post-MI surgery 
in the same set of LV samples that was previously used for analysis 
of Dio3 mRNA expression and Dio3 activity (8). Figure 5 shows 
that miR-214 expression levels did not increase significantly 
until day 5 following MI compared to sham-operated mice, 
and reached a plateau at post-MI day 7, which was maintained 
for at least 56  days without significant changes. Time-course 
analysis showed that Dio3 mRNA expression and Dio3 activity 
were already elevated at day 3 post-MI. Both Dio3 mRNA and 
Dio3 activity subsequently decrease toward a steady elevated 
level 56  days post-MI compared to sham-operated mice (8) 
(Figures 6A,B, respectively). These data indicate that the increase 
in Dio3 mRNA expression and Dio3 activity precede miR-214 
induction, suggesting that any mechanistic link between the two 
involves an effect of Dio3 activity on the expression of miR-214.
T3 Decreases cardiac mir-214 expression
The suggested regulation of miR-214 expression by increased Dio3 
expression would most likely be mediated by a local reduction in 
T3 levels induced by Dio3. In a previous study, we demonstrated 
that reduced T3 levels and reduced transcriptional activity of T3 
accompany the Dio3 induction in the post-MI heart. Therefore, 
we examined the effect of T3 on miR-214 expression in LV tissue 
of hypothyroid (−T3) and hypothyroid mice treated with T3 
for 3 days (+T3) mice. Exposure of the heart to high systemic 
levels of T3 resulted in a 50% reduction of miR-214 expression 
in the LV compared to the LV of hypothyroid mice (Figure 7). 
These findings suggest that reduced T3 levels may play a role in 
a negative feedback mechanism regulating Dio3 expression that 
involves miR-214.
DiscUssiOn
Several lines of evidence support the involvement of reduced 
TH-signaling in LV remodeling (14, 34, 35). The increased 
expression of the T3-degrading enzyme Dio3 in the failing heart 
provides the most likely explanation for the reduced TH-signaling 
and has emerged as a potential common denominator in the 
development of heart failure (7–11). However, the mechanism 
underlying the regulation of Dio3 expression in the heart remains 
largely unclear. Since Dio3 expression during development is 
known to be very precisely regulated in a spatiotemporal manner, 
miRNAs may be involved, as these regulators are known to play 
a role in fine-tuning of gene expression. The aim of the present 
FigUre 4 | Western blot analysis of DiO3 expression in vitro. (a) Transfection of COS-7 cells with increasing amounts of wtD3 plasmid confirmed the 
specificity of Ab 677 for full-length DIO3 (36 kDa) and of Ab 675 for truncated DIO3 protein (18 kDa). Equal amounts of protein were loaded. (B) COS-7 cells 
transfected with the CysD3 plasmid confirmed the expression of the truncated isoform of DIO3 in COS-7 cells transfected with the wtD3 plasmid, which was 
detected with Ab 675 (18 kDa) (lower blot; the upper blot is stained using Ab 677). (c) COS-7 cells were transfected with 100 ng of the wtD3 plasmid containing 
full-length human DIO3 together with either mimic-214 (DIO3 – 214) or Negative control miR-1 (DIO3-nc#1) at a final concentration of 500 nM. Addition of the 
negative control miR-1 did not significantly affect transfection efficiency (results not shown). Analysis of COS-7 cells transfected with empty pCDNA vector using Ab 
677 and Ab 675 did not show bands at 36 kDa and 18 kDa, respectively, confirming antibody specificity  (Figure S2 in Supplementary Material). Expression levels of 
the neomycin-resistance gene were analyzed using qPCR and used to normalize transfection efficiency. Values are means ± SEM, normalized to the value of the 
parameter in the DIO3-nc#1 group, *p < 0.05.
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study was to explore the possible involvement of miRNAs in 
the regulation of Dio3 in the remodeling LV of the mouse after 
MI. We show that Dio3 mRNA is a target of miR-214, and that 
this miRNA may play a role in a negative feedback mechanism 
regulating Dio3 expression in the post-MI heart, thereby limiting 
the decrease of cardiac T3 levels.
In silico analysis revealed that of all miRNAs that were shown to 
be differentially regulated in the post-MI mouse heart (25), miR-
214 was predicted to have the highest potential to target Dio3. 
This miRNA is suggested to play a role in the process of hyper-
trophy and heart failure in various models (21, 22, 27). Sequence 
analysis of the mouse Dio3 3′UTR predicted the presence of a 
miR-214 target site in the SECIS element, which was found to be 
highly conserved among species. Transfection experiments using 
a construct with a Renilla luciferase reporter gene containing the 
mouse Dio3 3′UTR demonstrated functional interaction of miR-
214 with Dio3 mRNA. The observed 30% reduction of reporter 
expression is comparable to the in vitro effects of miR-199b and 
FigUre 6 | Time course of mir-214 expression, Dio3 mrna and Dio3 activity after Mi. For the sake of clarity, the miR-214 data are shown in separate 
panels in combination with Dio3 mRNA expression (a) and Dio3 activity (B). The different parameters are expressed relative to their basal expression level 
determined in sham-operated mice at day 7. Dio3 mRNA and Dio3 activity data from this set of samples were published in part before (8). Values are means ± SEM, 
miR-214 (n = 5), Dio3 mRNA (n3d = 7, n5d = 6, n7d = 16, n28d = 10, n56d = 16) and Dio3 activity (n3d = 8, n5d = 9, n7d = 16, n28d = 6, n56d = 6).
FigUre 5 | Dio3 protein and mir-214 are co-expressed. Representative images of immunohistochemical staining for Dio3 (a) and miR-214 in situ hybridization 
(B) in sequential sections of LV tissue 7 days post-MI. The indicated area shows a group of cardiomyocytes expressing both Dio3 protein and miR-214, with 
adjoining cells negative for both. Bar = 100 μM.
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miR-214, targeting Dyrk1a and Ncx1, respectively, which have 
been shown to modify cardiac performance (22, 24).
An interesting feature of the conserved miR-214 target site in 
the 3′UTR of Dio3 is that it is located within the SECIS element, 
which is a secondary, double-stranded RNA structure. The SECIS 
element is responsible for the incorporation of selenocysteine 
(Sec) encoded by a UGA codon, which otherwise acts as a STOP 
codon (36). Impairment of the incorporation of Sec consequently 
results in a truncated form of DIO3 without deiodinase activ-
ity (33, 37, 38). We hypothesized that interference of miR-214 
with the SECIS element of DIO3 would result in increased levels 
of the truncated protein, and this was tested by analyzing the 
protein expression of full-length human DIO3 in COS-7 cells co-
transfected with miR-214 using Ab 677 to detect the full-length 
36 kDa DIO3 protein and Ab 675 to detect the 18 kDa truncated 
form of DIO3. Although miR-214 significantly affected DIO3 
protein expression, the levels of both full-length and truncated 
protein were equally reduced, indicating that miR-214 does not 
interfere with the insertion of Sec. However, the substantially 
greater relative reduction of DIO3 protein expression compared 
to the effect on the DIO3 mRNA level does suggest an additional 
effect of miR-214 on translation efficiency. Further research is 
needed to elucidate the mechanism of interaction of miR-214 in 
regulating DIO3 expression.
Having confirmed the suppressive effect of miR-214 on Dio3 
expression, it was unexpected that the expression of miR-214 
was increased in the post-MI mouse heart, given the marked 
upregulation of cardiac Dio3 activity in this model (8, 25). To 
explore the possible interplay between miR-214 and Dio3, their 
expression in cardiomyocytes was studied in sections of LV tissue. 
Immunohistochemical analysis of the post-MI LV confirmed the 
previously found heterogeneous expression of Dio3 protein (8). 
Also miR-214 exhibited a heterogeneous expression pattern, and 
analysis of serial sections indicated that Dio3 and miR-214 were 
co-expressed in cardiomyocytes, suggesting either that Dio3 and 
miR-214 are independently upregulated or that the expression of 
miR-214 and Dio3 expression is mechanistically linked. The latter 
option was supported by comparison of the temporal changes in 
miR-214 expression in the remodeling LV from the onset of MI 
up to 56 days later, with those of Dio3 mRNA and Dio3 activity 
FigUre 8 | Proposed mechanism of Dio3 regulation by mir-214. 
MI-induced cardiac stress results in upregulation of Dio3, leading to a 
reduced cardiac level of T3. The decreased level of T3 stimulates the 
expression of miR-214, which adds to the effects of other MI-induced 
regulatory pathways on miR-214 expression (the dotted arrow indicates that 
the relationship between T3 and miR-214 is inferred from indirect evidence). 
Increased miR-214 expression in turn decreases Dio3 expression, thereby 
dampening the reduction of T3 levels by Dio3. In this way, a negative 
feedback loop is created, possibly aimed at protecting the adult 
cardiomyocyte from the adverse effects of excessively low levels of T3.
FigUre 7 | effect of T3 treatment on the levels of mir-214 and Dio3 
mrna. Total RNA isolated from the LV of hypothyroid (−T3) and hypothyroid 
mice treated with T3 for three days (+T3) was analyzed by qPCR for miR-214 
expression using U6 snRNA as correction factor (a), and for Dio3 mRNA 
expression using Hprt as correction factor (B). Values are means ± SEM, 
n = 6, normalized to the −T3 values, *p < 0.05.
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as previously determined in the same samples. This showed that 
the increase of Dio3 mRNA levels and Dio3 activity [data from 
Ref. (8)] preceded the increase in miR-214 expression. While 
Dio3 mRNA levels and Dio3 activity were already increased to 
high levels at days 3–5 post-MI, miR-214 expression was still 
only modestly elevated. Furthermore, the expression of miR-214 
expression reached a maximum level at day 7 post-MI, by which 
time the Dio3 mRNA and Dio3 activity levels appeared to go 
down, but still remained elevated compared to sham. The expres-
sion of miR-214 remained, however, unchanged up to at least 
56 days post-MI. The increase of miR-214 over time is in line with 
previous results in a mouse MI model (26), showing increasing 
miR-214 expression levels over time in remote myocardium (26).
These data suggest a mechanistic link between miR-214 
and Dio3 expression, which could involve the Dio3-mediated 
reduction of cardiac T3 levels. This implies that expression of 
miR-214 is negatively regulated by T3, and this was confirmed 
by the finding that treatment of hypothyroid mice with T3 
markedly suppressed miR-214 expression levels in the LV. 
This may be a direct effect on transcription or processing of 
miR-214, but perhaps more likely involves components of the 
signal transduction pathways that drive physiological rather 
than pathological hypertrophy, and which are triggered by the 
effect of T3 on cardiac hemodynamic load (14, 30). Dio3 mRNA 
expression showed a reciprocal response, being higher in the LV 
of T3-treated mice compared to the LV of hypothyroid mice. 
This is in line with previous findings of stimulation of Dio3 
expression by high levels of T3 (39, 40). These studies provided 
evidence for a T3-dependent threefold induction of Dio3 expres-
sion after 24 h. Although suggestive of a direct transcriptional 
effect of T3, the mechanism of stimulation remained unclear. 
Our data suggest that in the post-MI heart, Dio3 expression may 
at least be additionally modulated by T3 via changes in miR-
214 expression. Taken together, the result of the present study 
support the involvement of miR-214 in a negative feedback 
mechanism regulating Dio3 expression. The proposed sequence 
of events is depicted in Figure  8. In the post-MI heart, Dio3 
expression is induced, possibly as part of the fetal gene program. 
This results in an increase in the local conversion of T3 to the 
inactive metabolite T2. We hypothesize that the documented 
local decrease of T3 levels stimulates the expression of miR-214, 
which dampens Dio3 expression. The relevance of this mecha-
nism lies in the prevention of an excessive decrease of cardiac 
T3 levels and the associated changes in expression of genes that 
are critical for cardiac function (14). MiR-214 expression is 
likely to be regulated by other mechanisms associated with the 
remodeling process in addition to the decreased T3 levels. It was 
shown that Hif-1α, which is a key determinant of progression in 
the remodeling LV (41), activates the locus dinamin 3 opposite 
site (Dnm3os) harboring miR-214 (27). Upregulation of Hif-1α 
after MI is generally observed in the infarct or peri-infarct zone, 
but Hif-1α-dependent transcription activity was found in the 
remote LV at day 5 post-MI (Pol, unpublished results), which 
may contribute to miR-214 upregulation.
In conclusion, this study first shows that miR-214 is able to 
target both the human and the mouse 3′UTR of DIO3, affecting 
mRNA and protein expression. Second, the results indicate a 
novel negative feedback mechanism regulating Dio3 expression 
in the post-MI mouse heart, in which a Dio3-mediated decrease 
of T3 levels results in increased expression miR-214, which subse-
quently reduces Dio3 expression. This mechanism may, therefore, 
be aimed at restoring, or limiting the reduction of T3 levels in the 
post-MI heart (Figure 8).
March 2016 | Volume 7 | Article 2210
Janssen et al. MicroRNA-214 and Cardiac Dio3 Regulation
Frontiers in Endocrinology | www.frontiersin.org
aUThOr cOnTriBUTiOns
RJ, CO, WP and WS designed the study. RJ, AM, AvM, ED and 
WS designed the experiments. RJ, MZ and AvM performed the 
experiments. RJ analyzed the data. RJ, AM and WS wrote the 
manuscript. WS and AM supervised the study.
acKnOWleDgMenTs
The authors thank Prof. D. Salvatore for providing antibody 718, 
and Prof. T. Visser for providing antibodies 675 and 677.
FUnDing
The Netherlands Cardiovascular Research Initiative (ARENA 
consortium, CVON 2011-11).
sUPPleMenTarY MaTerial




1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et  al. 
Heart disease and stroke statistics – 2014 update: a report from the American 
Heart Association. Circulation (2014) 129:e28–292. doi:10.1161/01.
cir.0000441139.02102.80 
2. Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial 
infarction: pathophysiology and therapy. Circulation (2000) 101:2981–8. 
doi:10.1161/01.CIR.101.25.2981 
3. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction 
between physiological and pathological cardiac hypertrophy: experimental 
findings and therapeutic strategies. Pharmacol Ther (2010) 128:191–227. 
doi:10.1016/j.pharmthera.2010.04.005 
4. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, et al. MicroRNAs 
in the human heart: a clue to fetal gene reprogramming in heart failure. 
Circulation (2007) 116:258–67. doi:10.1161/CIRCULATIONAHA.107.687947 
5. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac 
development and disease. Cardiovasc Res (2008) 79:562–70. doi:10.1093/cvr/
cvn137 
6. Dirkx E, da Costa Martins PA, De Windt LJ. Regulation of fetal gene expression 
in heart failure. Biochim Biophys Acta (2013) 1832:2414–24. doi:10.1016/j.
bbadis.2013.07.023 
7. Trivieri MG, Oudit GY, Sah R, Kerfant B-G, Sun H, Gramolini AO, et  al. 
Cardiac-specific elevations in thyroid hormone enhance contractility and 
prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci U 
S A (2006) 103:6043–8. doi:10.1073/pnas.0601072103 
8. Pol CJ, Muller A, Zuidwijk MJ, van Deel ED, Kaptein E, Saba A, et al. Left-
ventricular remodeling after myocardial infarction is associated with a cardio-
myocyte-specific hypothyroid condition. Endocrinology (2011) 152:669–79. 
doi:10.1210/en.2010-0431 
9. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, 
et  al. Hypoxia-inducible factor induces local thyroid hormone inactivation 
during hypoxic-ischemic disease in rats. J Clin Invest (2008) 118:975–83. 
doi:10.1172/JCI32824.the 
10. Olivares EL, Marassi MP, Fortunato RS, da Silva ACM, Costa-e-Sousa RH, 
Araújo IG, et  al. Thyroid function disturbance and type 3 iodothyronine 
deiodinase induction after myocardial infarction in rats a time course study. 
Endocrinology (2007) 148:4786–92. doi:10.1210/en.2007-0043 
11. Wassen FWJS, Schiel AE, Kuiper GGJM, Kaptein E, Bakker O, Visser TJ, et al. 
Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy 
and failure. Endocrinology (2002) 143:2812–5. doi:10.1210/endo.143.7.8985 
12. Berry MJ. Insights into the hierarchy of selenium incorporation. Nat Genet 
(2005) 37:1162–3. doi:10.1038/ng1105-1162 
13. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, et al. 
Cellular and molecular basis of deiodinase-regulated thyroid hormone signal-
ing. Endocr Rev (2008) 29:898–938. doi:10.1210/er.2008-0019 
14. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl 
J Med (2001) 344:501–9. doi:10.1056/NEJM200102153440707 
15. Huang SA, Mulcahey MA, Crescenzi A, Chung M, Kim BW, Barnes C, et al. 
Transforming growth factor-β promotes inactivation of extracellular thyroid 
hormones via transcriptional stimulation of type 3 iodothyronine deiodinase. 
Mol Endocrinol (2005) 19:3126–36. doi:10.1210/me.2005-0173 
16. Dentice M, Luongo C, Huang S, Ambrosio R, Elefante A, Mirebeau-Prunier 
D, et al. Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone 
action enhancing proliferation of normal and malignant keratinocytes. Proc 
Natl Acad Sci U S A (2007) 104:14466–71. doi:10.1073/pnas.0706754104 
17. Pol CJ, Muller A, Simonides WS. Cardiomyocyte-specific inactivation of thy-
roid hormone in pathologic ventricular hypertrophy: an adaptative response 
or part of the problem? Heart Fail Rev (2010) 15:133–42. doi:10.1007/
s10741-008-9133-7 
18. Ng L, Hernandez A, He W, Ren T, Srinivas M, Ma M, et al. A protective role 
for type 3 deiodinase, a thyroid hormone-inactivating enzyme, in cochlear 
development and auditory function. Endocrinology (2009) 150:1952–60. 
doi:10.1210/en.2008-1419 
19. Ng L, Lyubarsky A, Nikonov SS, Ma M, Srinivas M, Kefas B, et al. Type 3 deio-
dinase, a thyroid-hormone-inactivating enzyme, controls survival and mat-
uration of cone photoreceptors. J Neurosci (2010) 30:3347–57. doi:10.1523/
JNEUROSCI.5267-09.2010 
20. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 
(2009) 136:215–33. doi:10.1016/j.cell.2009.01.002 
21. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. 
A signature pattern of stress-responsive microRNAs that can evoke cardiac 
hypertrophy and heart failure. Proc Natl Acad Sci U S A (2006) 103:18255–60. 
doi:10.1073/pnas.0608791103 
22. Aurora AB, Mahmoud AI, Luo X, Johnson BA, van Rooij E, Matsuzaki S, et al. 
MicroRNA-214 protects the mouse heart from ischemic injury by controlling 
Ca2+ overload and cell death. J Clin Invest (2012) 122:1222–32. doi:10.1172/
JCI59327 
23. Callis TE, Pandya K, Seok HY, Tang R-H, Tatsuguchi M, Huang Z-P, et  al. 
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. 
J Clin Invest (2009) 119:2772–86. doi:10.1172/JCI36154 
24. da Costa Martins PA, Salic K, Gladka MM, Armand A-S, Leptidis S, el Azzouzi 
H, et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-am-
plification loop promoting calcineurin/NFAT signalling. Nat Cell Biol (2010) 
12:1220–7. doi:10.1038/ncb2126 
25. Janssen R, Zuidwijk M, Muller A, Mulders J, Oudejans CBM, Simonides WS. 
Cardiac expression of deiodinase type 3 (Dio3) following myocardial infarc-
tion is associated with the induction of a pluripotency microRNA signature 
from the Dlk1-Dio3 genomic region. Endocrinology (2013) 154:1973–8. 
doi:10.1210/en.2012-2017 
26. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall 
WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a 
role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A (2008) 105:13027–
32. doi:10.1073/pnas.0805038105 
27. el Azzouzi H, Leptidis S, Dirkx E, Hoeks J, van Bree B, Brand K, et al. The 
hypoxia-inducible microRNA cluster miR-199a~214 targets myocardial 
PPARδ and impairs mitochondrial fatty acid oxidation. Cell Metab (2013) 
18:341–54. doi:10.1016/j.cmet.2013.08.009 
28. de Waard MC, van der Velden J, Bito V, Ozdemir S, Biesmans L, Boontje NM, 
et al. Early exercise training normalizes myofilament function and attenuates 
left ventricular pump dysfunction in mice with a large myocardial infarction. 
Circ Res (2007) 100:1079–88. doi:10.1161/01.RES.0000262655.16373.37 
29. van den Bos EJ, Mees BME, de Waard MC, de Crom R, Duncker DJ. A 
novel model of cryoinjury-induced myocardial infarction in the mouse: a 
March 2016 | Volume 7 | Article 2211
Janssen et al. MicroRNA-214 and Cardiac Dio3 Regulation
Frontiers in Endocrinology | www.frontiersin.org
comparison with coronary artery ligation. Am J Physiol Heart Circ Physiol 
(2005) 289:H1291–300. doi:10.1152/ajpheart.00111.2005 
30. Janssen R, Zuidwijk MJ, Kuster DWD, Muller A, Simonides WS. Thyroid 
hormone-regulated cardiac microRNAs are predicted to suppress patho-
logical hypertrophic signaling. Front Endocrinol (Lausanne) (2014) 5:171. 
doi:10.3389/fendo.2014.00171 
31. Jørgensen S, Baker A, Møller S, Nielsen BS. Robust one-day in situ hybrid-
ization protocol for detection of microRNAs in paraffin samples using LNA 
probes. Methods (2010) 52:375–81. doi:10.1016/j.ymeth.2010.07.002 
32. Obernosterer G, Martinez J, Alenius M. Locked nucleic acid-based in  situ 
detection of microRNAs in mouse tissue sections. Nat Protoc (2007) 
2:1508–14. doi:10.1038/nprot.2007.153 
33. Kuiper GGJM, Klootwijk W, Visser TJ. Substitution of cysteine for seleno-
cysteine in the catalytic center of type III iodothyronine deiodinase reduces 
catalytic efficiency and alters substrate preference. Endocrinology (2003) 
144:2505–13. doi:10.1210/en.2003-0084 
34. Danzi S, Klein I. Thyroid hormone-regulated cardiac gene expression 
and cardiovascular disease. Thyroid (2002) 12:467–72. doi:10.1089/ 
105072502760143836 
35. Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail 
Rev (2010) 15:125–32. doi:10.1007/s10741-008-9125-7 
36. Low SC, Berry MJ. Knowing when not to stop: selenocysteine 
incorporation in eukaryotes. Trends Biochem Sci (1996) 21:203–8. 
doi:10.1016/0968-0004(96)10025-6 
37. Salvatore D, Low SC, Berry MJ, Maia AL, Harney JW, Croteau W, et al. Type 3 
lodothyronine deiodinase: cloning, in vitro expression, and functional analysis 
of the placental selenoenzyme. J Clin Invest (1995) 96:2421–30. doi:10.1172/
JCI118299 
38. Latrèche L, Jean-Jean O, Driscoll DM, Chavatte L. Novel structural deter-
minants in human SECIS elements modulate the translational recoding of 
UGA as selenocysteine. Nucleic Acids Res (2009) 37:5868–80. doi:10.1093/
nar/gkp635 
39. Deng WB, Liang XH, Liu JL, Yang ZM. Regulation and function of deiodinases 
during decidualization in female mice. Endocrinology (2014) 155:2704–17. 
doi:10.1210/en.2014-1015 
40. Sabatino L, Lubrano V, Balzan S, Kusmic C, Del Turco S, Iervasi G. Thyroid 
hormone deiodinases D1, D2, and D3 are expressed in human endothelial 
dermal microvascular line: effects of thyroid hormones. Mol Cell Biochem 
(2015) 399:87–94. doi:10.1007/s11010-014-2235-8
41. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite 
PA. Early expression of angiogenesis factors in acute myocardial isch-
emia and infarction. N Engl J Med (2000) 342:626–33. doi:10.1056/
NEJM200003023420904 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Janssen, Zuidwijk, Muller, van Mil, Dirkx, Oudejans, Paulus and 
Simonides. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
